Anti-obesity medications (AOMs), such as orlistat and phentermine, have long been used to treat patients, and recently, glucagon-like peptide 1 (GLP1) agonists have been introduced in the market for obesity treatment [2]. The gene discussed is GCG; the disease is obesity disorder.